Clinical Cases Podcast Series-FREE NO CME-Fentanyl 50 mcg TD Taper Example

Fentanyl 50 mcg TD Taper Example

Pdf Summary

This document is a patient/provider toolkit outlining a suggested taper plan for someone using a fentanyl 50 mcg/hr transdermal patch every 72 hours along with short-acting oxycodone (e.g., Percocet 10/325 mg or oxycodone IR 10 mg taken 3–4 times daily). It explains that tapering may be appropriate and should be done gradually with a clinician to maintain pain control and avoid significant withdrawal.<br /><br />Key safety and preparation steps include: prescribing naloxone and educating the patient/support person on its use to reduce overdose death risk; discussing non-opioid medications and nonpharmacologic pain treatments to support pain control and lessen withdrawal; using a calendar/medication box to track weekly dose changes; and selecting a taper pace that can be adjusted based on symptoms and provider guidance.<br /><br />The guidance emphasizes that when the fentanyl patch dose is reduced, the body needs 24–48 hours to adjust, so immediate-release (IR) oxycodone should be increased temporarily and taken exactly as directed. Specifically, when stepping down the fentanyl dose, the patient increases oxycodone at about the 18-hour mark (example: moving to 15 mg per dose, which equals 1.5 of a 10 mg tablet), then follows a schedule that gradually reduces oxycodone doses over subsequent days.<br /><br />A sample timetable is provided: fentanyl is reduced from 50 to 37 mcg/hr (Day 1), then to 25 mcg/hr (around Day 30), then to 12 mcg/hr (around Day 60), and discontinued around Day 120. Throughout, oxycodone dosing is adjusted in a structured way as fentanyl decreases. After the patch is stopped, the IR oxycodone can also be tapered further, with an example target of roughly a 10% monthly reduction in daily morphine milligram equivalents (MME) until the goal dose is reached.

Keywords

fentanyl taper

transdermal patch

oxycodone

opioid withdrawal

naloxone

pain management

dose reduction

morphine milligram equivalents

non-opioid therapies

clinician guidance